CARE-Melanoma Trial (CARE-Melanoma)
A Coordinated Approach to Peri-operative Rehabilitation to Enhance Outcomes in Melanoma: the CARE-Melanoma Pilot Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jenna Smith-Turchyn, PT, PhD
- Phone Number: 19058690599
- Email: smithjf@mcmaster.ca
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- melanoma diagnosis
- English speaking,
- adults (>18 years of age)
- scheduled to receive surgery after a neoadjuvant chemotherapy regime
Exclusion Criteria:
- <18 years of age
- are not undergoing neo-adjuvant chemotherapy
- self-report any chronic condition, cognitive impairment, or injury that would prevent them from participating independently in moderate intensity exercise
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CARE Intervention Group
This intervention group will include four peri-operative intervention sessions, the total intervention time will be approximately 4 months, with two of the intervention sessions will occur prior to surgery, and two occurring post-surgery.
At the pre-surgery sessions individuals with receive education on the benefits of exercise pre-treatment, how to exercise safely, and be set up with a tailored exercise routine by a trained physiotherapist.
They will set goals and action plans to work until their next session.
At the post-surgery sessions patients will review their function with the same physiotherapist and again be provided tailored recommendations to maximize their function.
|
Includes education on the benefit of exercise and how to exercise safely, rehabilitation to maximize strength, range of motion, and function, set up with a tailored exercise program by a trained physiotherapist or kinesiologist, goal setting and action planning.
|
|
No Intervention: Usual Care
This group will receive usual care (no rehabilitation intervention).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Retention rate
Time Frame: 4 months
|
Retention rate is the number of individuals enrolled in the study who complete the intervention.
|
4 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence rate
Time Frame: 4 months
|
Adherence in this project will be assessed by adherence to the rehabilitation session (measured as %).
|
4 months
|
|
Recruitment rate
Time Frame: 4 months
|
Recruitment rate is the percentage of eligible individuals approached for the study who enrol in the study.
|
4 months
|
|
Change in overall impairment score
Time Frame: 4 months
|
Measured via the Edmonton Symptom Assessment Scale at baseline and 4 month follow-up.
Minimum score: 0, Maximum score: 100 - higher scores represent higher levels of overall impairment.
|
4 months
|
|
Change in Physical Activity Level
Time Frame: 4 months
|
Measured via the Godin Leisure Time Exercise Questionnaire at baseline and 4 month follow-up.
Minimum score: 0, Maximum score: no max - higher scores represent higher levels of physical activity.
|
4 months
|
|
Change in functional mobility
Time Frame: 4 months
|
Measured via the 30 second sit to stand at baseline and 4 month follow-up.
Minimum score: 0, Maximum score: no max - higher scores represent higher levels of functional mobility.
|
4 months
|
|
Change in functional mobility
Time Frame: 4 months
|
Measured via the six minute walk test at baseline and 4 month follow-up.
Minimum score: 0, Maximum score: no max - higher scores represent higher levels of functional mobility.
|
4 months
|
|
Change in Grip Strength
Time Frame: 4 months
|
Measured via the handheld dynamometer at baseline and 4 month follow-up
|
4 months
|
|
Change in quality of life
Time Frame: 4 months
|
Measured via the Functional Assessment of Cancer Therapy (FACT)-Melanoma at baseline and 4 month follow-up.
Minimum score: 0, Maximum score: 204 - higher scores represent higher levels of quality of life.
|
4 months
|
|
Change in perception of health status
Time Frame: 4 months
|
Measured via the EQ-5D-3L VAS (no extended title) at baseline and 4 month follow-up.
Minimum score: 0, Maximum score: 100 - higher scores represent higher perceptions of health status.
|
4 months
|
|
Medication use
Time Frame: 4 months
|
Measured via a self-report scale at 4 month follow-up.
Minimum score: 0 (no medication used), Maximum score: no maximum - higher scores represent higher use of medications.
|
4 months
|
|
Change in range of motion
Time Frame: 4 months
|
Measured via the goniometer at baseline and 4 month follow-up
|
4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Skin Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Skin Neoplasms
- Skin and Connective Tissue Diseases
- Melanoma
- Therapeutics
- Patient Care
- Health Services
- Health Care Facilities Workforce and Services
- Aftercare
- Continuity of Patient Care
- Rehabilitation
Other Study ID Numbers
Other Study ID Numbers
- CARE-Melanoma
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.